Direct Intrahepatic Portocaval Shunt for Sinusoidal Obstruction Syndrome Associated with Hepatotoxicity of Pyrrolizidine Alkaloids
Table 1
Baseline characteristics of SOS cases.
Characteristic/group
A
B
value
Gender M/F
30/38
9/12
0.366
Age (mean (S.D.))
38.98±19.34
35.25±8.64
0.299
Child-PughA/B/C
3/55/10
1/11/9
0.328
MELD score (mean (S.D.))
12.49±7.25
13.17±9.16
0.145
Accompanied viral hepatitis
5
3
0.628
Chronic ethanol consumption
6
0
0
Cryptogenic hepatitis
2
0
0
Variceal hemorrhage(VH)
30
5
0.217
Refractory ascites(RA)
65
14
0.134
Both VH and RA
25
2
0
Laboratory tests
Alanine transaminase
249.73±192.12
182.05±81.30
0.595
Aspartate transaminase
383.98±289.49
301.05±214.01
0.604
Alkaline phosphatase
258.32±163.24
264.43±176.91
0.371
Gamma glutamyl transpeptidase
276.45±125.34
297.39±136.73
0.256
Total bilirubin
25.44±10.99
26.31±10.91
0.192
Albumin
29.37±9.25
28.61±9.72
0.261
Prothrombin time
16.24±7.69
18.15±8.46
0.135
Clinical presentations
Abdominal distention
67
18
0.154
Abdominal pain
24
13
0.364
Weakness
51
16
0.412
Poor appetite
63
19
0.346
Jaundice
48
12
0.216
Hepatomegaly
65
18
0.423
Splenomegaly
31
13
0.338
Pleural effusion
2
5
0
Lower limbs edema
12
3
0.026
Endoscopic therapy
48
15
0.128
Asites paracentesis
154
34
0.093
Seattle criteria
24
13
0.364
Baltimore criteria
18
9
0.379
No difference (P>0.05) could be seen in terms of age, sex, Child–Pugh score, and MELD score; laboratory tests, and clinical presentations. MELD, Model of End-stage Liver Disease; RA, refractory ascites; VH, variceal hemorrhage; laboratory tests and clinical presentations.
